# AbbVie vs Johnson & Johnson: stocks compared

URL: https://funkfolio.com/compare/abbv-vs-jnj

> AbbVie ($517.6B, P/E 50.6) and Johnson & Johnson ($670.9B, P/E 42.3) compared: size, valuation, margins, debt, cash and price change.

---

## AbbVie vs Johnson & Johnson

AbbVie (ABBV), health care, and Johnson & Johnson (JNJ), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Johnson & Johnson is worth $670.9B on the stock market and AbbVie $517.6B: Johnson & Johnson is valued at 30% more. AbbVie trades at 50.6 times earnings and Johnson & Johnson at 42.3. Over the past year AbbVie's share price has moved +25.9% and Johnson & Johnson's +41.3%.

### Key facts

- **AbbVie market value:** $517.6B
- **Johnson & Johnson market value:** $670.9B
- **AbbVie P/E:** 50.6
- **Johnson & Johnson P/E:** 42.3
- **AbbVie revenue:** $61.2B FY to 2025-12-31
- **Johnson & Johnson revenue:** $94.2B FY to 2025-12-28
- **Superinvestors holding both:** 10

Market values as of 18 Nov 2026, 06:23 UTC.

AbbVie vs Johnson & Johnson: every measure side by side

| Measure | AbbVie | Johnson & Johnson |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-28 |
| Size |  |  |
| Market cap | $517.6B lower | $670.9B higher |
| Revenue | $61.2B lower | $94.2B higher |
| Earnings | $4.2B lower | $26.8B higher |
| Employees | 57,000 lower | 138,200 higher |
| Total assets | $134B lower | $199.2B higher |
| Valuation |  |  |
| P/E | 50.6 higher | 42.3 lower |
| P/S | 8.5 higher | 7.1 lower |
| P/B | — | 8.2 |
| Dividend yield | 2.35% higher | 1.87% lower |
| Profitability |  |  |
| Operating margin | 24.6% | — |
| Balance sheet |  |  |
| Net assets | -$3.3B lower | $81.5B higher |
| Total liabilities | $137.2B higher | $117.7B lower |
| Total debt | $67.5B higher | $47.9B lower |
| Cash on hand | $5.2B lower | $19.7B higher |
| Price change |  |  |
| Today | -0.59% higher | -1.36% lower |
| 1 year | +25.9% lower | +41.3% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: AbbVie 125.1, Johnson & Johnson 139.6.

- AbbVie (ABBV)
- Johnson & Johnson (JNJ)

AbbVie and Johnson & Johnson share prices over one year, rebased to 100: AbbVie ends at 125.1, Johnson & Johnson at 139.6.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | ABBV | JNJ |
| --- | --- | --- |
| Nov 28, 2025 | 97.3 | 103.7 |
| Dec 31, 2025 | 97.6 | 103.7 |
| Jan 30, 2026 | 95.3 | 113.9 |
| Feb 27, 2026 | 99.2 | 124.5 |
| Mar 31, 2026 | 92.9 | 122.5 |
| Apr 30, 2026 | 90.3 | 115.2 |
| May 29, 2026 | 93.0 | 112.9 |
| Jun 30, 2026 | 107.5 | 127.3 |
| Jul 31, 2026 | 107.2 | 128.4 |
| Aug 31, 2026 | 109.6 | 133.2 |
| Sep 30, 2026 | 111.8 | 132.6 |
| Oct 30, 2026 | 126.0 | 136.9 |
| Nov 17, 2026 | 125.1 | 139.6 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (10)

- [Fred DiSanto](https://funkfolio.com/gurus/fred-disanto) 1.5% / 1.1%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.8% / 1.1%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.5% / 0.2%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.2% / 0.3%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.1% / 0.9%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 0.1% / 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) 0.1% / 0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1% / &lt;0.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) &lt;0.1% / &lt;0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1% / &lt;0.1%

#### AbbVie only (5)

- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.7%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.3%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.3%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 0.1%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) &lt;0.1%

#### Johnson & Johnson only (13)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 4.1%
- [Stephen Yacktman](https://funkfolio.com/gurus/stephen-yacktman) 4.0%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 4.0%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 2.6%
- [Tom Gayner](https://funkfolio.com/gurus/tom-gayner) 1.3%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.7%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.7%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.3%
- [Mario Gabelli](https://funkfolio.com/gurus/mario-gabelli) 0.2%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.1%
- [John Rogers](https://funkfolio.com/gurus/john-rogers) 0.1%
- [Christopher Bloomstran](https://funkfolio.com/gurus/christopher-bloomstran) &lt;0.1%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Johnson & Johnson). [Who owns ABBV](https://funkfolio.com/stock/ABBV/superinvestors) · [Who owns JNJ](https://funkfolio.com/stock/JNJ/superinvestors)

### More on AbbVie

- [AbbVie (ABBV) stock page](https://funkfolio.com/stock/ABBV)
- [AbbVie market cap](https://funkfolio.com/stock/ABBV/market-cap)
- [AbbVie revenue](https://funkfolio.com/stock/ABBV/revenue)
- [AbbVie P/E ratio](https://funkfolio.com/stock/ABBV/pe-ratio)
- [AbbVie operating margin](https://funkfolio.com/stock/ABBV/operating-margin)
- [AbbVie total debt](https://funkfolio.com/stock/ABBV/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Johnson & Johnson

- [Johnson & Johnson (JNJ) stock page](https://funkfolio.com/stock/JNJ)
- [Johnson & Johnson market cap](https://funkfolio.com/stock/JNJ/market-cap)
- [Johnson & Johnson revenue](https://funkfolio.com/stock/JNJ/revenue)
- [Johnson & Johnson P/E ratio](https://funkfolio.com/stock/JNJ/pe-ratio)
- [Johnson & Johnson operating margin](https://funkfolio.com/stock/JNJ/operating-margin)
- [Johnson & Johnson total debt](https://funkfolio.com/stock/JNJ/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### AbbVie against its closest peers

- [AbbVie vs Merck & Co](https://funkfolio.com/compare/abbv-vs-mrk)
- [AbbVie vs UnitedHealth Group](https://funkfolio.com/compare/abbv-vs-unh)
- [AbbVie vs Eli Lilly](https://funkfolio.com/compare/abbv-vs-lly)

#### Johnson & Johnson against its closest peers

- [Johnson & Johnson vs Eli Lilly](https://funkfolio.com/compare/jnj-vs-lly)
- [Johnson & Johnson vs Merck & Co](https://funkfolio.com/compare/jnj-vs-mrk)
- [Johnson & Johnson vs UnitedHealth Group](https://funkfolio.com/compare/jnj-vs-unh)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, AbbVie or Johnson & Johnson?**

By market value, Johnson & Johnson is the larger: $670.9B against $517.6B for AbbVie. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $61.2B for AbbVie.

**Which has the higher P/E ratio?**

AbbVie: 50.6, against 42.3 for Johnson & Johnson. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher dividend yield?**

AbbVie: 2.35%, against 1.87% for Johnson & Johnson. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

AbbVie: $67.5B, against $47.9B for Johnson & Johnson. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both AbbVie and Johnson & Johnson?**

In their latest 13F filings, Fred DiSanto, Ken Fisher, Ken Griffin, Cliff Asness, Mairs & Power team, Jensen team, Murray Stahl, Thomas Russo, Howard Gleicher and Rajiv Jain hold both.

### Cite this page

Funkfolio, “AbbVie vs Johnson & Johnson”, data as of 18 November 2026. https://funkfolio.com/compare/abbv-vs-jnj

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
